Incyte (INCY) Interest Coverage Ratio (2010 - 2026)
Incyte (INCY) reported Interest Coverage Ratio of 529.2 for Q1 2026, up 70.24% on a YoY basis from 310.86 in Q1 2025, and down 8.3% quarter-over-quarter from 577.08 in Q4 2025.
Incyte (INCY) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Incyte has reported Interest Coverage Ratio for 17 years, with the latest figure at 529.2 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 70.24% year-over-year to 529.2; the trailing twelve-month figure through Mar 2026 stood at 689.26 (up 890.66% YoY), and the FY2025 full-year result was 623.91, up 2218.09% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 529.2, down from 577.08 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 892.78 in Q2 2025, with the low at 727.75 in Q2 2024.
- Historically, Interest Coverage Ratio has averaged 308.66 across 5 years, with a median of 295.85 in 2023.
- The largest YoY upside for Interest Coverage Ratio was 304.65% in 2024 against a maximum downside of 345.99% in 2024.
- Incyte's Interest Coverage Ratio stood at 105.09 in 2022, then soared by 121.65% to 232.92 in 2023, then soared by 208.94% to 719.6 in 2024, then decreased by 19.81% to 577.08 in 2025, then decreased by 8.3% to 529.2 in 2026.
- The last three Interest Coverage Ratio figures came in at 529.2 (Q1 2026), 577.08 (Q4 2025), and 749.19 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 529.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 529.20 |
| Dec 31, 2025 | 577.08 |
| Sep 30, 2025 | 749.19 |
| Jun 30, 2025 | 892.78 |
| Mar 31, 2025 | 310.86 |
| Dec 31, 2024 | 719.60 |
| Sep 30, 2024 | 188.74 |
| Jun 30, 2024 | -727.75 |
| Mar 31, 2024 | 213.72 |
| Dec 31, 2023 | 232.92 |
| Sep 30, 2023 | 344.63 |
| Jun 30, 2023 | 295.85 |
| Mar 31, 2023 | 52.81 |
| Dec 31, 2022 | 105.09 |
| Sep 30, 2022 | 215.88 |
| Jun 30, 2022 | 375.27 |
| Mar 31, 2022 | 171.38 |
| Dec 31, 2021 | 147.25 |
| Sep 30, 2021 | 536.24 |
| Jun 30, 2021 | 393.40 |